BioWorld

Jan. 12, 2004

View Archived Issues

Cypress Partners Milnacipran In Union Worth Up To $250M

Cypress Bioscience Inc. could receive between $200 million and $250 million through a deal for milnacipran, its Phase III product for fibromyalgia syndrome, a common cause of chronic and widespread pain. (BioWorld Today) Read More

$19M Private Placement Ranks As Cortex's 'Biggest Financing'

Read More

With $18.9M Series B, Hydra Has Cash To Last Into 2007

Read More

Perlegen Signs AstraZeneca, Plus Two Deals With Pfizer

Read More

Other News To Note

Read More